Revised contraindications for the use of non-medical WB-electromyostimulation. Evidence-based German consensus recommendations.
arteriosclerosis
cancer
contraindications
diabetes mellitus
neurologic diseases
whole-body electromyostimulation
Journal
Frontiers in sports and active living
ISSN: 2624-9367
Titre abrégé: Front Sports Act Living
Pays: Switzerland
ID NLM: 101765780
Informations de publication
Date de publication:
2024
2024
Historique:
received:
23
01
2024
accepted:
01
04
2024
medline:
1
5
2024
pubmed:
1
5
2024
entrez:
1
5
2024
Statut:
epublish
Résumé
Whole-body electromyostimulation has proven to be a highly effective alternative to conventional resistance-type exercise training. However, due to adverse effects in the past, very extensive contraindications have been put in place for the commercial, non-medical WB-EMS market. Considering recent positive innovations e.g., federal regulation, mandatory trainer education, revised guidelines, and new scientific studies on WB-EMS application, we believe that a careful revision of the very restrictive contraindications on WB-EMS is needed. This applies all the more because many cohorts with limited options for conventional exercise have so far been excluded. During a first meeting of an evidence-based consensus process, stakeholders from various backgrounds (e.g., research, education, application) set the priorities for revising the contraindications. We decided to focus on four categories of absolute contraindications: "Arteriosclerosis, arterial circulation disorders", "Diabetes mellitus" (DM), "Tumor and cancer" (TC), "Neurologic diseases, neuronal disorders, epilepsy". Based on scientific studies, quality criteria, safety aspects and benefit/risk assessment of the category, DM and TC were moved to the relative contraindication catalogue, while arteriosclerosis/arterial circulation disorders and neurologic diseases/neuronal disorders/epilepsy were still considered as absolute contraindications. While missing evidence suggests maintaining the status of neurologic diseases/neuronal disorders as an absolute contraindication, the risk/benefit-ratio does not support the application of WB-EMS in people with arteriosclerosis/arterial circulation diseases. Despite these very cautious modifications, countries with less restrictive structures for non-medical WB-EMS should consider our approach critically before implementing the present revisions. Considering further the largely increased amount of WB-EMS trials we advice regular updates of the present contraindication list.
Identifiants
pubmed: 38689869
doi: 10.3389/fspor.2024.1371723
pmc: PMC11058671
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1371723Informations de copyright
© 2024 von Stengel, Fröhlich, Ludwig, Eifler, Berger, Kleinöder, Micke, Wegener, Zinner, Mooren, Teschler, Filipovic, Müller, England, Vatter, Authenrieth, Kohl and Kemmler.
Déclaration de conflit d'intérêts
The authors declare the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.